+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Eliquis (Apixaban) Market Size, Share & Trends Analysis Report By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

  • PDF Icon

    Report

  • 150 Pages
  • July 2025
  • Region: Global
  • Grand View Research
  • ID: 6154572
Description Jump to:
The global Eliquis (apixaban) market size was estimated at USD 20.70 billion in 2024 and is projected to reach USD 18.87 billion by 2033, with a decline of CAGR of -2.2% from 2025 to 2033, primarily due to loss of patent exclusivity, growing generic competition, and consequent price erosion across major markets.

The increasing global burden of atrial fibrillation (AF) and venous thromboembolism (VTE) has emerged as a major driver for the Eliquis (Apixaban) market. AF significantly raises the risk of stroke, prompting greater use of anticoagulants for long-term prevention. In June 2022, the Journal of Clinical Medicine published a meta-analysis of over 3.9 million adults with atrial fibrillation, assessing apixaban's safety and effectiveness. The study found that apixaban had favorable outcomes compared to other anticoagulants, with lower stroke risks, mortality, and major bleeding. Eliquis has become a preferred option due to its favorable safety profile and minimal need for monitoring. Clinical guidelines in cardiology have expanded the use of direct oral anticoagulants, leading to broader adoption across primary and specialty care. As AF and VTE cases rise, particularly among aging populations, the demand for reliable and easy-to-administer anticoagulants such as Eliquis continues to grow.

Shifts in clinical practice toward direct oral anticoagulants have strengthened Eliquis's market position. Healthcare providers value DOACs for their predictable pharmacokinetics, fixed dosing, and lower risk of major bleeding events than warfarin. Eliquis has shown superior results in large-scale trials, contributing to its high prescription rates worldwide. Patients benefit from simplified treatment regimens that improve adherence and reduce healthcare visits. As transitioning from traditional anticoagulants to DOACs accelerates, Eliquis is well-positioned to capture a growing share of the global anticoagulant market.

Global Eliquis (Apixaban) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global Eliquis (apixaban) market report based on indication, distribution channel, and region:

Indication Outlook (Revenue, USD Million, 2021 - 2033)

  • Atrial Fibrillation (AF)
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Post-Operative Venous Thromboembolism (VTE) Prophylaxis
  • Others

Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Eliquis (Apixaban) Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Eliquis (Apixaban) Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2033
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
4.4. Atrial Fibrillation (AF)
4.4.1. Atrial Fibrillation (AF) Market, 2021 - 2033 (USD Million)
4.5. Deep Vein Thrombosis (DVT)
4.5.1. Deep Vein Thrombosis (DVT) Market, 2021 - 2033 (USD Million)
4.6. Pulmonary Embolism (PE)
4.6.1. Pulmonary Embolism (PE) Market, 2021 - 2033 (USD Million)
4.7. Post-Operative Venous Thromboembolism (VTE) Prophylaxis
4.7.1. Post-Operative Venous Thromboembolism (VTE) Prophylaxis Market, 2021 - 2033 (USD Million)
4.8. Others
4.8.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Eliquis (Apixaban) Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2033
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
5.5. Retail Pharmacies
5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
5.6. Online Pharmacies
5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
Chapter 6. Eliquis (Apixaban) Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Eliquis (Apixaban) Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Distribution Channel Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Distribution Channel Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Distribution Channel Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
6.5.1. Europe Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Distribution Channel Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Distribution Channel Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Distribution Channel Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Distribution Channel Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Distribution Channel Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Distribution Channel Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Distribution Channel Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Distribution Channel Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Distribution Channel Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Distribution Channel Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Distribution Channel Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Distribution Channel Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Distribution Channel Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Distribution Channel Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Distribution Channel Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Japan Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Distribution Channel Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. China Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Distribution Channel Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Distribution Channel Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Distribution Channel Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Distribution Channel Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Eliquis (Apixaban) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. F. Hoffmann-La Roche Ltd.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Mylan NV
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Teva Pharmaceutical Industries Ltd.
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Sanofi
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Pfizer Inc.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. GSK plc
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Novartis AG
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. AstraZeneca
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Johnson & Johnson Private Limited
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Bristol-Myers Squibb Company
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Eliquis (apixaban) market, by region, 2021 - 2033 (USD Million)
Table 4 Global Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 5 Global Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 6 North America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
Table 7 North America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 8 North America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 9 U.S. Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 10 U.S. Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 11 Canada Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 12 Canada Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 13 Mexico Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 14 Mexico Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 15 Europe Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
Table 16 Europe Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 17 Europe Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 18 UK Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 19 UK Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 20 Germany Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 21 Germany Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 22 France Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 23 France Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 24 Italy Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 25 Italy Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 26 Spain Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 27 Spain Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 28 Norway Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 29 Norway Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 30 Denmark Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 31 Denmark Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 32 Sweden Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 33 Sweden Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 34 Asia Pacific Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
Table 35 Asia Pacific Eliquis (apixaban) market, by indication, 2021 - 2033 (USD
Table 36 Asia Pacific Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 37 Japan Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 38 Japan Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 39 China Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 40 China Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 41 India Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 42 India Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 43 Australia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 44 Australia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 45 South Korea Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 46 South Korea Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 47 Thailand Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 48 Thailand Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 49 Latin America Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
Table 50 Latin America Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 51 Latin America Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 52 Brazil Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 53 Brazil Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 54 Argentina Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 55 Argentina Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 56 Middle East & Africa Eliquis (apixaban) market, by country, 2021 - 2033 (USD Million)
Table 57 Middle East & Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 58 Middle East & Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 59 South Africa Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 60 South Africa Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 61 Saudi Arabia Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 62 Saudi Arabia Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 63 UAE Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 64 UAE Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
Table 65 Kuwait Eliquis (apixaban) market, by indication, 2021 - 2033 (USD Million)
Table 66 Kuwait Eliquis (apixaban) market, by distribution channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Eliquis (apixaban) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Eliquis (apixaban) market dynamics
Fig. 12 Eliquis (apixaban) market: Porter’s five forces analysis
Fig. 13 Eliquis (apixaban) market: PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Atrial Fibrillation (AF) market, 2021 - 2033 (USD Million)
Fig. 16 Deep Vein Thrombosis (DVT) market, 2021 - 2033 (USD Million)
Fig. 17 Pulmonary Embolism (PE) market, 2021 - 2033 (USD Million)
Fig. 18 Post-Operative Venous Thromboembolism (VTE) Prophylaxis market, 2021 - 2033 (USD Million)
Fig. 19 Others market, 2021 - 2033 (USD Million)
Fig. 20 Distribution channel market, 2021 - 2033 (USD Million)
Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 23 Online Pharmacies market, 2021 - 2033 (USD Million)
Fig. 24 Eliquis (apixaban) market revenue, by region
Fig. 25 Regional marketplace: Key takeaways
Fig. 26 North America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 27 U.S. country dynamics
Fig. 28 U.S. Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 29 Canada country dynamics
Fig. 30 Canada Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 31 Mexico country dynamics
Fig. 32 Mexico Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 33 Europe Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 34 UK country dynamics
Fig. 35 UK Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 36 Germany country dynamics
Fig. 37 Germany Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 38 France country dynamics
Fig. 39 France Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 40 Italy country dynamics
Fig. 41 Italy Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 42 Spain country dynamics
Fig. 43 Spain Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 44 Norway country dynamics
Fig. 45 Norway Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 46 Sweden country dynamics
Fig. 47 Sweden Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 48 Denmark country dynamics
Fig. 49 Denmark Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 50 Asia Pacific Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 51 Japan country dynamics
Fig. 52 Japan Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 53 China country dynamics
Fig. 54 China Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 55 India country dynamics
Fig. 56 India Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 57 Australia country dynamics
Fig. 58 Australia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 59 South Korea country dynamics
Fig. 60 South Korea Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 61 Thailand country dynamics
Fig. 62 Thailand Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 63 Latin America Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 64 Brazil country dynamics
Fig. 65 Brazil Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 66 Argentina country dynamics
Fig. 67 Argentina Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 68 MEA Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 69 South Africa country dynamics
Fig. 70 South Africa Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 71 Saudi Arabia country dynamics
Fig. 72 Saudi Arabia Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 73 UAE country dynamics
Fig. 74 UAE Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 75 Kuwait country dynamics
Fig. 76 Kuwait Eliquis (apixaban) market, 2021 - 2033 (USD Million)
Fig. 77 Company categorization
Fig. 78 Company market position analysis
Fig. 79 Strategic framework

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Bristol-Myers Squibb Company

Related Topics

Related Reports

Factor Xa Inhibitor Market - A Global and Regional Analysis: Focus on Application, Route of Administration, and Region - Analysis and Forecast, 2025-2035 - Product Image

Factor Xa Inhibitor Market - A Global and Regional Analysis: Focus on Application, Route of Administration, and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Andexxa (Ondexxya) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Andexxa (Ondexxya) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Antithrombotic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028) - Product Image

Antithrombotic Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • Report
  • 120 Pages
  • Global
From
Japan Antiplatelet Drugs Market Report and Forecast 2025-2034 - Product Image

Japan Antiplatelet Drugs Market Report and Forecast 2025-2034

  • Report
  • 250 Pages
  • Japan
From
Apixaban - Global Strategic Business Report - Product Image

Apixaban - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.